Computer Simulation Model System for Interpretation and Validation of Algorithms for Monitoring of Cancer Patients by Use of Serial Serum Concentrations of Biomarkers in the Follow-Up After Surgical Procedures and Other Treatments - A Computer Simulation by Flemming Lund et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
14 
Computer Simulation Model  
System for Interpretation and Validation  
of Algorithms for Monitoring of Cancer  
Patients by Use of Serial Serum  
Concentrations of Biomarkers  
in the Follow-Up After Surgical 
 Procedures and Other Treatments  
– A Computer Simulation Model  
System Based on the  
Breast Cancer Biomarker TPA 
Flemming Lund1, György Sölétormos1,  
Merete Frejstrup Pedersen1 and Per Hyltoft Petersen1,2 
1Department of Clinical Biochemistry, Hillerød Hospital, University of Copenhagen,  
2Norwegian Quality Improvement of Primary Care Laboratories (NOKLUS),  
Section for General Practice, University of Bergen, Bergen,  
1Denmark 
2Norway 
1. Introduction 
Concentrations of biomarkers for cancers (tumour markers) in plasma vary over time, and 
the ideal biomarker is a component which reflects the size of the tumour. Optimal 
interpretation of serial data on biomarkers during monitoring of patients following 
treatment of malignant disease is therefore vital for early prediction of reappearance of the 
tumour or metastases. Consequently, an ideal tumour biomarker will signal such 
reappearance before being detected by other relevant methods. On the other hand any false 
positive signals which can lead to superfluous investigations and unnecessary anxiety for 
the patient must be avoided. Because the biomarkers are produced in small amounts and 
released to plasma during healthy conditions, and because concentrations in plasma vary 
over time, it is necessary to be able to distinguish between true and false signals when serial 
measurements after treatment are to be interpreted. Here, different algorithms are proposed 
in literature, and this chapter deals with validation of some of these algorithms designed for 
the biomarker TPA (tissue polypeptide antigen) used in follow-up in treated breast 
tumours.  
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In contrast to the common statistics used for comparing two or several groups or some 
distributions, the purpose with the algorithms for bio-markers is to decide at each sampling 
and measurement time whether there is a reappearance of the tumour and whether or not 
there are metastases. 
Several algorithms to interpret serial measurements of these markers for monitoring have 
been proposed and used in clinical trials. The simplest algorithm, used by all kit 
manufactures and included in their inserts, as also published by Barak et al. (1990), is a cut-
off which defines relapse when the marker concentration exceeds this concentration. All 
algorithms include a cut-off, either directly in the interpretation or indirectly as an algorithm 
to be used either below or above the cut-off value. Some algorithms are based on two 
measurements (e.g. a minimum and the latest measured value) and crossing of the cut-off 
limit, while others include rules for the size of a critical difference of 25 % (Tondini & Hayes, 
1989) or a doubling (Söletormos et al., 1996) or significant change (Söletormos et al., 1996) 
according to the reference change value (RCV) concept introduced by (Harris & Yasaka, 
1983). An increase of 25% either below or above the cut-off for both measured 
concentrations (Dinistrian et al., 1991), and also a doubling or significant change when all 
measurements are above the cut-off value has been proposed (Söletormos et al., 1996). 
Others are based on three measurements, where the last measurement is a third, 
confirmatory test for the increase, and these have also been recommended when crossing 
the cut-off (Chan et al. 1997; Molina et al., 1995; Nicolini et al., 1991; Söletormos et al., 1996), 
in addition to algorithms where all measurements are below the cut-off (Bonfrer, 1990) as 
well as for situations where all measurements are above the cut-off (Bonfrer, 1990; Mughal 
et al., 1983; Söletormos et al., 1996). 
All these algorithms give different signals for the same monitoring data, and a comparison 
of outcomes in the form of true positive and false positive results based on computer 
simulations of relevant monitoring situations has been performed (Söletormos et al., 2000b). 
These illustrate for each algorithm the advantages in terms of time to detection of 
reappearance, and disadvantages in the form of false positive signals. The basic biological 
and clinical data for estimated values of within-subject biological variation of serum-TPA 
(CVB) during steady-state are available (Söletormos et al., 2000a). The rates of exponential 
increases in serum TPA during tumour growth are based on monitoring data from breast 
cancer patients (Söletormos et al., 2000a). 
It has been demonstrated by Iglesias et al. (2005) that, for monitoring, the benefit of using 
the RCV (Harris & Yasaka, 1983) compared to a cut-off depends on the distance between the 
cut-off and the first measured concentration of the difference between two consecutive 
measurements to be compared to the RCV. When this distance is small, the probability of 
crossing the cut-off by the second measurement is higher than the probability of obtaining a 
significant change between the two measurements. Larger distances speak in favour of the 
reference change value. 
The purpose of this chapter is to demonstrate the influence of the distance between the cut-
off and the initial (baseline) concentration for TPA in serum in a simulation study like the 
paper on the tumour marker CA 15-3 (Petersen et al., 2011). This is done by challenging the 
different algorithms, where crossing the cut-off is part of the criterion, by computer 
simulations of various situations of monitoring breast cancer, imitating various exponential 
increases corresponding to recurrent cancer and a range of values of biological variation in 
order to validate the algorithms. 
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2. Interpretation of serial TPA concentrations 
2.1 Materials and methods 
The materials were data and parameters for breast cancer patients obtained from the 
literature (Söletormos et al., 1996; Söletormos et al., 2000a). 
2.1.1 Cut-off 
The cut-off concentration for TPA during treatment and follow-up of women with breast 
cancer is 95 U/L, recommended by the manufacture of the TPA kit (AB Sangtec Medical, 
Bromma, Sweden). 
2.1.2 Steady-state, biological and analytical variation 
The variations during the stable period of monitoring breast cancer patients are considered 
as steady-state and expressed as within-subject biological variation (CVB) and analytical 
variation (CVA) according to Sölétormos et al. (2000a). However, the within-subject 
biological variation, CVB, is not homogeneous. Therefore CVB for 5th, 50th and 95th 
percentile has been used with the analytical variation CVA as a constant. 
For TPA the 50th percentile for within-subject biological variation, CVB%, is 24.5% and 
analytical variation, CVA%, is 8.4%. 
For TPA the 95th percentile of within-subject biological variation, CVB%, is 48.9% and 
analytical variation, CVA%, is 8.4% 
For TPA the 5th percentile of within-subject biological variation, CVB%, is 8.5% and 
analytical variation, CVA%, is 8.4% (Söletormos et al., 2000a). 
2.1.3 Tumour biomarker increase 
The estimated values for the rate of increase (λ) in biomarkers after relapse in women with 
breast cancer are available (Söletormos et al., 2000a). The increase is assumed to be 
exponential (eλt) and the λ-values for the 5%, 50%, and 95% percentiles are 0.0132, 0.0346, 
and 0.0907, respectively (Söletormos et al., 2000a). 
2.1.4 Algorithms 
Barak et al. {1}: 
Two consecutive measurements. The first below and the second above cut-off (Barak et al., 
1990). 
Tondini & Hayes {2}: 
At least two measurements. The last measurement is above cut-off and at least 25% higher 
than any previous measurement below the cut-off concentration (Tondini & Hayes, 1989). 
Söletormos et al. A {3}: 
At least two measurements. The last measurement is above cut-off and at least twice 
(doubling) of any previous measurement below the cut-off (Söletormos et al., 1996). 
www.intechopen.com
 
Biomarker 
 
298 
Chan et al. {4}: 
Three consecutive measurements. The last and middle concentrations are both above the 
cut-off and the first is below the cut-off (Chan et al., 1997). 
Söletormos et al. B {5}: 
At least three measurements. The last concentration is higher than the penultimate 
concentration and both are above the cut-off. The penultimate concentration is significantly 
higher than any previous measurement below the cut-off (Söletormos et al., 1996). 
Molina et al. {6}: 
Three consecutive measurements. The first concentration is below twice the cut-off 
(doubling) and the last two are both above twice the cut-off (doubling) (Molina et al., 1995). 
Nicolini et al. {7}: 
Three consecutive measurements. The first measured concentration is below the cut-off. The 
middle concentration is above the cut-off and the last measured concentration is >30 % 
higher than the middle measured concentration (Nicolini et al., 1991). 
2.1.5 Methods 
The basic principles and methods have been presented previously (Petersen et al., 2011; 
Söletormos et al., 2000b), and the basic model and the additional calculations of results for 
the varying start concentrations of TPA between the cut-off and these initial concentrations 
are described in detail below. 
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Illustration of simulated data for steady-state concentrations (-●-), with a mean concentration 50 U/L, 
CVB = 24.5% and CVA = 8.5%. Baseline (starting) concentration 50 U/L and the cut-off concentration, 95 
U/L, (- - - -). Sampling frequency every two months (61 days). 
Fig. 1A. Steady-state graph 
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Illustration of simulated data for steady-state concentrations (-●-), with a mean concentration 50 U/L, 
CVB = 24.5% and CVA = 8.5%, and tumours with exponential growth λ = 0.0132 (-■-)), according to 0.95* 
eλ*t U/L. Baseline (starting) concentration 50 U/L and the cut-off concentration, 95 U/L, (- - - -). 
Sampling frequency every two months (61 days). 
Fig. 1B. Steady-state and tumour growth graphs. 
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Illustration of simulated data for steady-state concentrations (-●-), with a mean concentration 50 U/L, 
CVB = 24.5% and CVA = 8.5%, and tumour with exponential growth λ = 0.0132 (-■-)),according to 0.95* 
eλ*t U/L. Baseline (starting) concentration for the course is 50 U/L and the cut-off concentration, 95 U/L, 
(- - - -). Sampling frequency every two months (61 days). The (-○-) graph is the addition result of steady-
state concentrations (-●-) plus 0.95* eλ*t U/L. 
Fig. 1C. Steady-state, tumour growth and resulting graphs. 
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Tumour marker as a function of time
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The same as fig. 1C except chanced scale of concentrations U/L. The resulting graph and the 
exponential graph will in time be nearly indistinguishable, here after approx. 500 days. 
Fig. 1D. Steady-state, tumour growth and resulting graphs.  
2.1.6 Basic simulation 
Simulation of concentration data using Microsoft Excel version 2003. 
2.1.7 Steady-state 
For each patient, a series of ”concentrations” of biomarker was calculated from simulated 
data as a function of time ‘after treatment’. For each ‘sample’ during steady-state conditions, 
the resulting concentration value (cij) is calculated from a chosen ‘steady-state’ concentration 
(cs-s) with the addition of a random number (randomi) from a Gaussian distribution 
multiplied by ‘the steady-state within-subject biological variation’ (CVB), plus a new random 
number (randomj) from a Gaussian distribution multiplied by the analytical variation (CVA) 
according to the model (Bliss, 1967):  
cij = cs-s * [1 + randomi * CVB %/100 + randomj * CVA %/100] 
This is performed for 50 samples in series, numbered from 1 to 50 and each corresponding 
to a specific day of monitoring when sampling is performed every two months (61 days), 
and further performed for each patient with new random Gaussian numbers for a total of 
1000 surrogate patients. The result is a series of random concentration values with a mean 
close to the chosen value (cs-s). Fig. 1A illustrates a steady-state situation, where the 
fluctuations are based on within- subject biological variation (CVB) plus analytical 
imprecision variation (CVA). 
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2.1.8 Tumour growth 
Based on data from Sölétormos et al. (1997, 2000a), increases in biomarkers are shown to be 
associated with progression of disease and it is found that the concentrations of biomarkers 
have an exponential relation with time. However, the rate of tumour growth can vary 
considerably. The rate of increase is expressed as  in the exponential function as a factor in 
the exponent in et or as exp(t). The rate of increase  (also called slope) was calculated for 
TPA in patients Sölétormos et al. (2000a) and found as 5th percentile ( = 0.0132), as 50th 
percentile ( = 0.0346) and as 95th percentile ( = 0.0907). Therefore, in the simulation model 
tumour growth is described as an exponential increase in the biomarker TPA. The start 
concentration (t = 0) of the biomarker originating from the tumour is arbitrarily selected as 
an amount corresponding to a concentration 100 times lower than the cut-off concentration 
(0.95 U/L). The resulting function of the TPA from the tumour is then expressed as 0.95et or 
as 0.95 exp(t). See Fig 1B as an example of an exponential tumour growth where   
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Illustration of simulated data for steady-state concentrations (-●-), with a mean concentration 50 U/L 
and CVB = 24.5% and CVA = 8.5%., and tumours with exponential growth  = 0.0132 (-○-),  = 0.0346(-+-) 
, and  = 0.0907 (-x-) according to 0.95* e*t U/L. Baseline (starting) concentration for the four courses is 
50 U/L and the cut-off concentration, 95 U/L, (- - - -). Sampling frequency every two months (61 days). 
Fig. 2. Different rates of tumour growth increase. 
As a resulting graph the tumour concentration is now added to the steady-state concentration 
(steady-state concentration + initial tumour (0.95 U/L)). An example is illustrated in Fig 1C. 
At first, the resulting graph has nearly the same concentration as the steady-state graph, but 
after some time TPA products from the tumour take over as the dominating contributor. 
Thereafter steady-state concentrations might be neglected as the resulting graph will be close 
to the exponential tumour graph (see Fig 1D). This process is repeated until a total of 1000 
‘patient pathways’ are evaluated using the same parameters. In Fig 2 is illustrated an 
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example of the resulting graphs from 3 different rates of tumour increases (slopes = λ) and a 
steady-state situation where λ = 0. When λ is high, the biomarker will increase fast and 
correspondingly the smaller slopes will show later increases. 
2.1.9 Testing the algorithms by application to the simulated data 
For each ‘patient’, the investigated algorithm is applied in sequential order and when a 
sample is positive according to the algorithm, it is recorded as a positive biomarker signal 
(POS). Summing up all the 1000 simulated ‘patients’, the percentage that are positive in each 
sample number (same days) is calculated, resulting in a growing graph in a plot of 
percentage biomarker positive as a function of sample number or day/months. This is 
illustrated in figure 3 for four different values of including zero (= steady-state). 
The slopes become steeper for increasing λ-values, which means that the detection of 
tumour growth is earlier for fast growing tumours, as expected. The POS signals for the 
steady-state situation ( = 0.000) represent false positive signals (in the example in Fig. 3 it is 
0% after 600 days, approximately 20 months). In steady-state, POS signals will be recorded as 
false positive because no tumour growth is simulated, and therefore the POS signals cannot 
be considered true positives. For the three other graphs, the POS signals are recorded as true 
positives because an exponential tumour growth is simulated. In validation of the different 
algorithms, the time for 100% POS is important, but from a theoretical point of view, the  
most interesting variables are the lowest -values (0.000 and 0.0123), which are the most 
difficult to distinguish - and at the same time very important for follow-up of tumour-
producing biomarkers after surgery, chemotherapy etc.  
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Illustration of the algorithm from Barak et al.{1} considered POS when the concentration first exceeds 
the cut-off (TPA = 95U/L). Percentage POS as a function of time for four different exponential increases 
with  = 0.0132 (-○-),  = 0.0346 (-+-), and  = 0.0907 (-x-) according to 0.95* e*t U/L. The steady-state 
simulation is represented by λ = 0.0000 (-●-). 
Fig. 3. Percentage positive patients (POS) as a function of time.  
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2.1.10 Varying steady-state and start (baseline) concentrations 
For each algorithm, a number of steady-state and start concentrations are used (2.38, 4.75, 
9.5, 14.3, 19.0, 23.8, 28.5, 38.0, 47.5, 57.0, 66.5, 76.0, 85.5, and 95.0 U/L) where the 
concentration in the first ‘sample’ is fixed at 0.1 % below the stated concentration in order to 
ensure that at least one sample from each ‘patient’ is below the cut-off threshold. The 
percentage of positives at a certain time/sample is illustrated as a function of the starting 
concentration for each algorithm (see e.g. Fig 4). 
2.1.11 Biological variation of tumour growth 
As defined in the tumour growth situation, the exponential function is added to the steady-
state including a biological variation CVB. This exponential function can further be varied by 
multiplying the concentration due to the exponential function by a random factor times 0.25, 
which corresponds to an extra biological variation in tumour growth of 25 %. 
As previously defined, the tumour growth is expressed as an exponential function: 0.95*eλt, 
where λ is the slope and t is the time (days or months). The 25% extra biological variation 
within the tumour growth is then expressed with: 
(1 + randomk*0.25)*0.95*eλt, 
where randomk is a new random number from a Gaussian distribution, and the start 
concentration of tumour growth is still expressed by the factor 0.95, when t = 0, i.e. 1% of 
cut-off concentration. 
2.2 Results  
Results for each algorithm are presented with illustrations of the characteristics for each 
algorithm.  
2.2.1 Algorithm {1} Barak et al. 
Two consecutive measurements. The first below and the second above the cut-off (Barak et 
al., 1990). 
In Fig. 4, the fastest tumour growth (λ = 0.0907) is 100 % percentages positive (POS) after 
two months for all start concentrations (sample 2), whereas the remaining graphs have 
almost the same development, with POS increasing from 0% at approximately 57 U/L to 
approximately 50% POS at 95 U/L. After six months (sample 4), the next lower slope ( λ = 
0.0346) reaching 100% POS for all start concentrations, whereas the lowest slope (λ = 0.0132) 
and steady-state (λ = 0.0000) slowly increase to approximately 85% POS near the cut-off of 95 
U/L. At ten months (sample 6), the slowest tumour growth has separated from the steady-
state concentrations, increasing from 0 to 100% POS for starting concentrations between 30 
and 70 U/L, and false positive (FP) is still zero up to approximately 57 U/L, but has 
increased to 97% at 95 U/L.  
It is clear from Fig. 4 that true positive (TP) graphs increase with increasing starting 
concentrations, whereas FP graphs are zero for the low starting concentrations and increase 
over time for starting concentrations above 57 U/L.  
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Percentage positive (POS) as a function of starting concentration (TPA U/L) for algorithm {1} Barak et 
al. after 2 months (sample 2), 6 months (sample 4) and 10 months (sample 6). Same slope symbols as in 
Fig. 2.  
Fig. 4. Percentages positive signals at three different times.  
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With the only criterion as crossing the cut-off, the algorithm {1} from Barak et al. is very 
simple. In this way the time for progression detection is short – however the percentages of 
FP are unacceptably high - especially with start concentrations near cut-off - i.e. from approx 
57 U/L to cut-off (95 U/L). After 1 year the FP is 98% near the cut-off.  
In comparison with the other algorithms, which all have more restrictive criteria for 
recording a positive signal (POS) as in progression of tumour growth, the percentage of FP 
results decreases. Table 1 lists FP after one and two years, and the algorithm Barak et al. {1} 
has the highest FP (i.e. 98%) rate in ‘patients’. However, if the start concentration is below 57 
U/L, the algorithm Barak et al. {1} has only few percentages FP (i.e. 3%) and at the same 
time the fastest detection time for progression. Only Tondini & Hayes {2} has comparable 
“good” POS results for TPA. 
2.2.2 Algorithm {2} Tondini & Hayes 
Two consecutive measurements. The last measurement is above the cut-off and at least 25% 
higher than any previous concentration below the cut-off value (Tondin & Hayes, 1989). 
The only difference between algorithm Barak et al. {1} and algorithm Tondini & Hayes {2} is 
that, in the latter algorithm, the criterion is 25% higher concentration above cut-off 
compared to the lowest value below cut-off. Many (simulated) patients will be recorded 
similarly as algorithm Barak et al. {1} - especially with low start concentration. Therefore, the 
performances of these two algorithms are comparable. Algorithm Tondini & Hayes {2} 
shows only moderately lower percentages of positives (POS) for the lower tumour growths 
and the steady-state situation at 6 months, i.e. also slightly lower FP between 55 and 95 U/L 
during the first half of the year (compare Fig. 4 and Fig. 5 at sample 4). 
Although there are a few more restrictions in algorithm Tondini & Hayes {2}, the detection 
time for TP patients is practically the same – however, the percentage of FP is still 
unacceptable with start concentrations near cut-off. 
2.2.3 Algorithm {3} Sölétormos et al. A 
At least two measurements. The last measurement is above cut-off and at least 100% higher 
than any previous measurement below the cut-off (doubling) (Söletormos et al., 1996). 
This algorithm is comparable to the algorithm Tondini & Hayes {2}. The only difference is 
that the increase is not 25% but 100% for the last concentration over cut-off. In other words 
the three first algorithms are very similar. 
The slightly more restrictive criterion with algorithm Söletormos et al. A {3} results in much 
lower FP signals with start concentrations near cut-off (see Fig. 5). For example the 
percentages of FP signals are reduced from 98% by algorithm Barak et al. {1} to 32% by 
algorithm Söletormos et al. A {3} after 1 year just below 95 U/L (cut-off) (see Table 1). 
However, after 6 months it is not possible to distinguish between the slowest tumour 
growth and healthy steady-state patients (see Fig. 5). Comparison of the algorithm from 
Söletormos et al. A {3} with Barak et al. {1} and Tondini & Hayes {2} shows nearly the same 
results with low start concentrations (below 57 U/L) where all three algorithms have only 
few FP signals. 
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Comparison of the algorithms of algorithm {2} Tondini & Hayes, and algorithm {3} Söletormos et al. A 
at 6 months (sample 4). Percentage positive (POS) as a function of starting concentration as for Fig. 3. 
The only difference between the two algorithms is the size of increase after crossing the cut-off, i.e. 25% 
and 100%, respectively. For symbols see Fig. 3. 
Fig. 5. Comparison of two different algorithms. 
All three algorithms have also the same tumour detection time – except Söletormos et al. A 
{3} which has extended the time by two months for the slowest tumour growth (see Table 1). 
The next four algorithms presented here - all have a characteristic in common – they all need 
at least three measurements. As a consequence, the earliest detection time for tumour 
progression is 4 months. In Table 1, these algorithms are marked with a footnote: ‘Three 
sample points are needed’. 
2.2.4 Algorithm {4} Chan et al. 
Three consecutive measurements. The last and penultimate concentrations are both above 
the cut-off, and the first measured concentration is below cut-off (Chan et al., 1997). 
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The algorithm Chan et al.{4} appears similar to algorithm Barak et al. {1} with the addition of 
a confirmation of crossing the cut-off. When the graph is crossing the cut-off (95 U/L) - the 
next sample should also be above cut-off. In this way the percentage FP signals may be 
reduced – from 98% FP by algorithm Barak et al. {1} to 64% FP by algorithm Chan et al. {4} 
after 1 year below 95 U/L. As a consequence - the detection times are correspondingly 2 
months later for all 3 slopes. 
Algorithm Slope 
0.0907: 
100% at 
time 
Slope 
0.0346: 
100% at 
time 
Slope 
0.0123: 
100% at 
time 
False 
positive 
below 
95 U/L 
at 1 year 
False 
positive 
below 95 
U/L at 2 
years 
False 
positive 
below 57 
U/L at 1 
year 
False 
positive 
below 57 
U/L at 2 
years 
Barak  
et al. {1} 
2 months 6 months 12 months 98% 100% 3% 4% 
Tondini 
and  
Hayes {2} 
2 months 6 months 12 months 91% 100% 3% 4% 
Söletormos 
et al. A {3} 
2 months 6 months 14 months 32% 70% 2% 3% 
Chan  
et al. {4} 
[4 months]1 8 months 14 months 64% 91% 0% 0% 
Söletormos 
et al. B {5} 
[4 months]1 8 months 16 months 6% 24% 0% 0% 
Molina  
et al. {6} 
[4 months]1 8 months 16 months 0% 0% 0% 0% 
Nicolini  
et al. {7} 
[4 months]1 [8 months]2[14 months]3 6% 10% 0% 0% 
1Three sample points are needed for the algorithm. 2 Only at start concentrations below 57 U/L obtain 
100%. 3Only at start concentrations below 28 U/L obtain 100%. 
Times for detection of 100 % tumour progression using the different algorithms are listed for three 
slopes. Percentages of false positive results after 1 and 2 years with TPA start concentrations below 95 
U/L and 57 U/L for each algorithm are also listed. All results are generated from 1000 computer 
simulations. 
Table 1. Performance results from seven algorithms. 
2.2.5 Algorithm {5} Sölétormos et al. B 
At least three measurements. The last measured concentration is higher than the 
penultimate concentration, both above the cut-off, and higher than the third to last 
measured concentration. The penultimate concentration is significantly higher than any 
previous measurements below the cut-off (Söletormos et al., 1996). 
In a comparison of algorithm Chan et al. {4} with algorithm Söletormos et al. B {5}, the latter 
algorithm is much more restrictive in recording positive signals (POS). The last 
measurement demands an increase compared to the penultimate value – and this 
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penultimate value has to have a significant increase compared to earlier measurements (see 
below). The more restrictive criteria are shown to give much lower FP signals – even after 
two years, the percentages of FP results are 24% compared to 91% at algorithm Chan et al. 
{4} below 95 U/L. Again more restrictive criteria have a ‘cost’ in regard to detection time - 
here at the slowest slope, which is extended by two months at algorithm Söletormos et al. B 
{5}. On the other hand these algorithms show only 0% FP results at low start concentrations, 
i.e. below 57 U/L. 
The significant increase, or reference change value (RCV), was introduced by Harris and 
Yasaka (1983) in order to detect a significant change in consecutive measurements, and was 
defined as RCV = 1.96*2½*CVB, where the 1.96 is the standard deviation from a Gaussian 
distribution corresponding to a two-tailed probability of 5 %, and 2½ relates to the variation 
of differences CVDifference = (CVB2 + CVB2)½ or the CVB2 can be substituted by the combination 
of biological and analytical variation. The calculation in the computer system is the test of 
the difference between two consecutive measurements (as a percentage) in regard to the 
RCV.  
2.2.6 Algorithm {6} Molina et al. 
Three consecutive measurements. The first is below cut-off and the next two measurements 
are both over double the cut-off value (Molina et al., 1995). 
This algorithm Molina et al. {6} is comparable with algorithm Chan et al. {4} - a confirmation 
of crossing cut-off with an extra sample - but at algorithm Molina et al.{6}, there is a 
doubling of the cut-off (to 190 U/L). 
This very restrictive criterion results in 0% FP results – even also near cut-off. This algorithm 
has the lowest number of FP, i.e. 0%, in comparison to all the other algorithms. And, again, 
strict restrictions inhibit the ability to detect early tumour progression – algorithm Molina et 
al. {6} has the longest detection time shared with algorithm Söletormos et al.B {5} and 
algorithm Nicolini et al {7}. 
2.2.7 Algorithm {7} Nicolini et al. 
Three consecutive measurements. The first measured concentration is below the cut-off, the 
middle measured concentration is above the cut-off and the last is more than 30% higher 
than the middle value (7). 
The algorithm Nicolini et al. {7} can also be compared with algorithm Chan et al. A crossing 
of cut-off has to be confirmed by a new sample – but this new sample has to be 30% higher 
compared to the second measurement over cut-off.  
This 30% higher concentration for the two last measurements is difficult to fulfil for the two 
slowest tumour growths for starting concentrations just below the cut-off. The exponential 
function simulated from tumour growth has to have some time before an increase effect is 
observed in the results. As a consequence, the graphs decrease with increasing starting 
concentrations without the possibility of giving a positive signal (POS), because when 
crossing the cut-off too slowly, there will never be a POS signal. This is illustrated in Fig. 6 
where the graphs for sample 10 and sample 13 are almost identical.  
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Percentage positive (POS) as a function of starting concentration for algorithm {7} Nicolini et al. after 1 
year (sample 7), after 18 months (sample 10), and after two years (sample 13). After sample 8 (14 
months) the figures will ”freeze” and be identical for the three tumour slopes. 
Fig. 6. Results from Algorithm {7} Nicolini et al. at different times 
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It has to be underlined that, in this way, the algorithm Nicolini et al. {7} will never achieve 
100% POS with start concentrations near cut-off. The 100% POS will only be fulfilled at start 
concentrations below 28 U/L, for the two slowest slopes (see footnotes in Table 1) 
2.2.8 Overall results 
The characteristics for the seven algorithms are summarised in Table 1 with the time for 
100% true positive results (TP) for each slope of tumour growth, and with percentage false 
positive (FP) at two years for both start concentrations of 57 U/L and 95 U/L (cut-off). 
The two first algorithms (Barak et al. {1} and Tondini & Hayes {2}) in Table 1 show the 
fastest time to detect 100% positive signals in patients for each of the investigated three 
slopes. However, these algorithms also show the highest percentage of false positive (FP) 
signals, both after 1 and 2 years. All the other algorithms also show FP results of lower and 
varying percentages - except algorithm Molina et al. {6} with zero FP. The algorithm Molina 
et al. {6} on the other hand also needs the longest time for 100% positive results shared with 
algorithm Söletormos et al. B {5}. The algorithm Nicolini et al. {7} has partly the same long 
time, but only at start concentrations below 57 U/L and below 28 U/L for the slopes 0.0346 
and 0.0132, respectively. Above these start concentrations, the algorithm Nicolini et al. {7} 
will never obtain 100% positive results (see also Fig 6). In other words after 14 months the 
two slowest slopes will “freeze” and have the same results. Only FP percentages will 
increase slowly. 
Overall, all the algorithms are comparable when the start concentrations are below 57 U/l 
with only few FP results for the algorithms from Barak et al. {1}, Tondini & Hayes {2} and 
Söletormos et al. A {3}. The other algorithms are even better as regards the percentage of FP 
results. However, they need longer time for detection of tumour progression. 
In the clinical situation, when the TPA start concentration is below 57 U/L, it should be 
recommended to use the algorithm Barak et al. {1} in order to obtain an early detection of 
tumour progression. However, when the TPA start concentration is above 57 U/L and up 
to just below 95 U/L, it should be recommended to use the algorithm Molina et al. {6}– 
even with a longer detection of tumour progression – in order to avoid any false positive 
signals.  
In a clinical situation using the Nicolini et al. {7} algorithm, several patients with slow 
tumour growth and with high biomarker (TPA) start concentration near cut-off will never 
be recorded as positive tumour patients – hopefully treatment action will be taken based on 
high concentrations or other clinical signals. 
In this investigation the performances of the algorithms have been studied using results 
from the biomarker TPA. The same procedure has been used on the same algorithms with 
results from the biomarker CA 15-3 (Petersen et al., 2011). The results from these two 
investigations are very similar. The properties from the algorithms on detection time of 
progression, the percentages of false positive patients (FP), the dependence on start 
concentration both near cut-off and approx half cut-off – all the overall characteristic results 
and figures from each algorithm were relatively identical using different biomarkers, i.e. 
TPA and CA 15-3. 
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These results indicate that the relative performance of the investigated algorithms for early 
detection of tumour progression and avoiding FP results – seems to be independent of the 
biomarker in the present model and set-up. 
It must be underlined that this statement may only be valid based on general considerations. 
For example biomarkers with relative low steady-state variation combined with high rates of 
tumour increase may change some of the algorithm performances according to the detection 
time of progression and percentage of FP signals. In this situation the performance from 
algorithm Nicolini et al. {7} could be better, because start concentration near cut-off may 
achieve 100% TP signals within an acceptable timeframe compared with a never ending 
timeframe in this TPA investigation. Nevertheless, the relative information from the 
algorithms on performance will still stand. In other words - the best ability to detect tumour 
progression will often be obtained by using the algorithm from Barak et al. {1} and the best 
ability to get low FP signals will often be obtained by using the algorithm from Molina et al. 
{6} - and this is noteworthy: independent of the biomarker. 
2.2.9 Performance of the algorithms with impact from extreme values of within-
subject biological variation (CVB) 
An important assumption for calculation of within-subject biological variation as the square 
root of the mean of the variances from the individual coefficients of variation of reference 
individuals in projects on biological variation is that these variations are distributed 
homogeneously. If there is variance homogeneity, this pooled coefficient of variance 
represents all individuals of the reference group and it is correct to use this pooled CVB in 
the simulations as a factor for the random Gaussian values. This assumption, however, is 
not fulfilled for TPA (Sölétormos et al. 2000a), where the range of coefficients of variation 
goes from 8.5% and 48.9% and represents individual CVB-values, from which the extreme 
values used for the challenging of algorithms in the simulations are selected. 
The results in Table 1 are based on CVB = 24.5% (within-subject biological variation). This 
value is based on a 50th percentile from an investigation on 127 patients (Söletormos et al., 
2000b). Due to the lack of variance homogeneity, we have also investigated the impact on 
the results from the algorithms based on a 95th percentile where CVB = 48.9%. 
The results for CVB = 48.9% are listed in Table 2 where it can be seen that the detection times 
for tumour progression are practically the same as for the 50th percentile of biological 
variation. Only algorithm Söletormos et al. B {5} shows a 2 months later detection time for a 
slope of 0.0123. Nearly all algorithms show an increased percentage of false positive signals 
(the four first algorithms are already close to 100 % for CVB, = 24.5% for the highest start 
concentrations) with the higher biological variation CVB. Only the algorithm Molina et al. {6} 
maintains 0% FP results in situations with high biological variations. It should also be noted 
that the algorithm results from Söletormos et al. A {3} and Söletormos et al. B {5} both 
markedly increase the number of FP results, when the biological variation, CVB, is high and 
the start concentration is below cut-off. For Söletormos et al. B {5} this is partly due to the 
algorithm, where the significant change in the criterion is based on the 50th percentile of 
biological variation CVB = 24.5% whereas the simulation is based on the much higher 
extreme CVB = 48.9%. Consequently the use of significant change in the algorithm makes it 
sensitive to lack of variance homogeneity.  
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Algorithm Slope 0.0907: 
100% at time
Slope 0.0346: 
100% at time
Slope 0.0123: 
100% at time
False-
positive 
below 
95 U/L 
at 1 year 
False 
positive 
below 95 
U/L at 2 
years 
False 
positive 
below 57 
U/L at 1 
year 
False 
positive 
below 57 
U/L at 2 
years 
Barak  
et al. {1} 
2 months 
(2 months)
6 months 
(6 months) 
12 months 
(12 months)
98% 
(98%) 
100% 
(100%) 
45% 
(3%) 
70% 
(4%) 
Tondini and 
Hayes {2} 
2 months 
(2 months)
6 months 
(6 months) 
12 months 
(12 months)
95% 
(91%) 
100% 
(100%) 
45% 
(3%) 
70% 
(4%) 
Söletormos 
et al. A {3} 
2 months 
(2 months)
6 months 
(6 months) 
14 months 
(14 months)
76% 
(32%) 
98% 
(70%) 
35% 
(2%) 
65% 
(3%) 
Chan  
et al. {4} 
[4 months]1
([4months]1)
8 months 
(8 months) 
14 months 
(14 months)
65% 
(64%) 
91% 
(91%) 
6% 
(0%) 
13% 
(0%) 
Söletormos 
et al. B {5} 
[4 months]1
([4months]1)
8 months 
(8 months) 
18 months 
(16 months)
19% 
(6%) 
47% 
(24%) 
3% 
(0%) 
7% 
(0%) 
Molina  
et al. {6} 
[4 months]1
([4months]1)
8 months 
(8 months) 
16 months 
(16 months)
0% 
(0%) 
0% 
(0%) 
0% 
(0%) 
0% 
(0%) 
Nicolini  
et al. {7} 
[4 months]1
([4months]1)
[8 months]2 
([8 months]2)
[14 months]4
([14 months]3)
16% 
(6%) 
29% 
(10%) 
0% 
(0%) 
0% 
(0%) 
1Three sample points are needed for the algorithm. 2 Only at start concentrations below 57 U/L obtain 
100%. 3Only at start concentrations below 28 U/L obtain 100%. 4 Only at start concentration below 19 U/L. 
Test of robustness of the algorithms when the biological variation, CVB, is increased from 24.5% to 
48.9%. Times for detection of tumor progression using the different algorithms are listed for three 
slopes. Percentages false positive results (FP) after 1 and 2 years with TPA start concentrations below 95 
U/L and 57 U/L for each algorithm are also listed. All results are generated from 1000 computer 
simulations. Results from biological variation of CVB = 48.9% and CVB = 24.5% just below in (brackets). 
Table 2. Performance of seven algorithms with increased biological variation. 
On the other hand the results indicate that the algorithm from Molina et al. {6} is most 
robust against increased biological variation CVB values. 
In the other extreme situation with a very low biological variation 5th percentile (CVB = 
8.5%), the performances from the algorithms are listed in Table 3. 
The most striking results in the table is the impact from low biological variation CVB on the 
false positive number (FP) from algorithm Söletormos et al. A {3} and algorithm Söletormos 
et al. B {5}. These algorithms show low percentage of FP results, when the biological 
variation CVB is low – and on the other hand - a high number of FP results when the 
biological variation CVB is high, as discussed above. It should also be noted that the 
detection time for the slowest slope is two months earlier for Söletormos et al. A {3}, who at 
the same time show very low percentages of FP signals. In a clinical situation with a patient, 
where the biological variation is known to be low, the best algorithm for interpreting 
www.intechopen.com
Computer Simulation Model System for Interpretation  
and Validation of Algorithms for Monitoring of Cancer Patients by Use of Serial Serum... 
 
313 
monitoring biomarker results will thus be the algorithm Söletormos et al. A {3}. In this 
situation very early detection times are combined with very low FP signals. It is notable that 
the algorithms {1} Barak et al., {2} Tondini and Hayes and {4} Chan et al. for the high start 
concentrations have high percentages of FP after two years.  
Algorithm Slope 0.0907: 
100% at time
Slope 
0.0346: 100% 
at time 
Slope 0.0123: 
100% at time
False-
positive 
below 
95 U/L 
at 1 year 
False 
positive 
below 95 
U/L at 2 
years 
False 
positive 
below 57 
U/L at 1 
year 
False 
positive 
below 57 
U/L at 2 
years 
Barak  
et al. {1} 
2 months 
(2 months)
6 months 
(6 months)
12 months 
(12 months)
98% 
(98%) 
100% 
(100%) 
0% 
(3%) 
0% 
(4%) 
Tondini and 
Hayes {2} 
2 months 
(2 months)
6 months 
(6 months)
12 months 
(12 months)
65% 
(91%) 
94% 
(100%) 
0% 
(3%) 
0% 
(4%) 
Söletormos 
et al. A {3} 
2 months 
(2 months)
6 months 
(6 months)
12 months 
(14 months)
1% 
(32%) 
1% 
(70%) 
0% 
(2%) 
0% 
(3%) 
Chan  
et al. {4} 
[4 months]1 
([4months]1)
8 months 
(8 months)
14 months 
(14 months)
68% 
(64%) 
92% 
(91%) 
0% 
(0%) 
0% 
(0%) 
Söletormos 
et al. B {5} 
[4 months]1 
([4months]1)
8 months 
(8 months)
14 months 
(16 months)
0% 
(6%) 
0% 
(24%) 
0% 
(0%) 
0% 
(0%) 
Molina  
et al. {6} 
[4 months]1 
([4months]1)
8 months 
(8 months)
16 months 
(16 months)
0% 
(0%) 
0% 
(0%) 
0% 
(0%) 
0% 
(0%) 
Nicolini  
et al. {7} 
[4 months]1 
([4months]1)
[8 months]2
([8 months]2)
[14 months]2
([14 months]3)
0% 
(6%) 
0% 
(10%) 
0% 
(0%) 
0% 
(0%) 
1Three sample points are needed for the algorithm. 2 Only at start concentrations below 57 U/L obtain 
100%. 3Only at start concentrations below 28 U/L obtain 100%. 
Test of robustness of the algorithms when the biological variation is decreased from CVB = 24.5% to CVB 
= 8.5%. Times for detection of tumor progression using the different algorithms are listed for three 
slopes. Percentages false positive results after 1 and 2 years with TPA start concentrations below 95 U/L 
and 57 U/L for each algorithm are also listed. All results are generated from 1000 computer 
simulations. Results from biological variation of CVB = 8.5% and CVB = 24.5 % just below in (brackets). 
Table 3. Performance of seven algorithms with decreased biological variation. 
In conclusion, the most robust algorithm against biological variation is the algorithm Molina 
el al. {6}. And the most sensitive algorithms with influence from biological variations CVB 
are the algorithms Söletormos et al. A {3} and Söletormos et al. B {5}. 
2.2.10 Biological variation of tumour growth 
Just as we have investigated the impact of biological variation, CVB, on the performance in a 
steady-state situation, we have also challenged the variation in progression conditions. Thus, 
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we have included a variation of 25% with the selected three slopes in the simulation model 
and compared the results with the results in Table 1. 
Nearly all the results were close to the same as in Table 1 when this variation of 25% was 
included in the exponential function. The false positive (FP) results chanced only a few per 
cent for the most algorithms and maximum increases in percentages were 4% found at the 
algorithms Barak et al. {1} and Tondini & Hayes {2} below 57 U/L after two years. 
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Percentage positive patients (POS) as a function of starting concentrations for algorithm Barak et al. {1} 
after one year. The upper figure shows results from the “normal” rate of increase. The figure below 
shows results from a modified rate of increase, including biological variation in the exponential 
function of tumour growth of 25%. For the slowest slope (λ =0.0132) (---o---), the modified slope shows a 
reduced number of percentage positives from start concentration 0 up to approx 57 U/L TPA with 
percentage positives increasing from 78% to 100%, respectively.  
Fig. 7. Impact of biological variation on exponential tumour growth. 
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Also the detection times for progression using the three slopes with biological variation 
were nearly the same as the results without variation. An example of the minor changes in 
results including variation of tumour growth is illustrated in Fig. 7. Results from the  
algorithm Barak et al.{1} include a variation of exponential function of 25%; only the slowest 
slope for tumour growth shows a slightly reduced number of percentages of positive results 
compared to the “normal” slope. The most marked change was found with algorithm 
Söletormos et al. A {3}. This algorithm showed two months extended detection time at the 
middle fast slope (λ = 0.0346) – and similarly the algorithm Molina et al. {6} showed two 
months extended detection time at the slowest slope. 
Overall, the biological variation of tumour growth has only minimal effects on the results 
and does not change the conclusions based on results in Table 1; it may therefore be 
excluded from further computer simulation investigations. 
3. Conclusion 
The start concentration of the biomarker TPA is a very important parameter in the 
examination of the performance of the algorithm, i.e. time for detection of progression and 
percentage of false positive results (FP). Start concentrations near cut-off will give more FP 
in nearly every algorithm – but the algorithms with low FP results also have longer tumour 
detection time. All the investigated algorithms performed comparable in FP results, when 
the start concentration was low, i.e. below 57 U/L. 
These overall conclusions are relatively identical to the conclusion on results from the same 
algorithms using biomarker CA 15-3 (Petersen et al., 2011) – this indicates that the relative 
performance of algorithms is independent of the biomarker. 
Differences in biological variation, CVB, have an influence on the performance of nearly all 
the algorithms. Only the algorithm Molina et al {6} has unchanged results with the different 
biological variations, CVB, – in other words this algorithm is the most robust against 
increasing biological variation CVB. Some algorithms show better performance when the 
biological variation CVB is low. When the biological variation CVB is low the algorithm 
Söletormos et al. A {3} has the best performance as regards early progression detection and 
simultaneously low number of FP results. 
The biological variation of the tumour growth up to 25% has only a minor influence on the 
performance of the algorithms and does not chance the overall conclusions. 
In a clinical situation the start concentration should be the point for selecting the best 
algorithm. When the start concentration is near the cut-off, the algorithm Molina et al. {6} 
could be used to avoid too many FP results. When the start concentration is below 57 U/L, 
the algorithm Barak et al. {1} could be used to have a short progressive detection time with 
only few FP results. 
3.1 Computer simulations 
A summary of new important conclusions from this investigation: 
a. The relative performances of algorithms are independent of the biomarker. 
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b. Some algorithms are more robust against increased biological variation than others. 
c. Variation in tumour growth has only limit impact on the performances of the 
algorithms. 
These conclusions are based on computer simulations. In the computer simulations, the 
steady-state variation and the rate of tumour increase (λ = slope) are based on clinical data 
from the literature and the simulations are based on random counts generated from a 
Gaussian distribution from the computer multiplied by the parameters borrowed from 
publications. Furthermore, the cost-price for the clinical investigations compared with 
computer simulation is enormous and the computer simulation is a convenient, easy and 
quick method to compare algorithm performances based on the same simulated data-points. 
Thus, computer simulation should be a tool to select the "right" algorithm before a clinical 
investigation regarding for example low number of false positive (FP) signals. Computer 
simulations are thus not a substitute for clinical investigations, but a supplementary tool in 
helping to interpret biomarker variations and challenge the algorithms with extreme 
parameters in the model. 
Thus, the advantage of computer simulations is that it is relatively easy to vary the 
parameters in the simulation model and examine the impact on the performances of the 
algorithms. In this investigation we have investigated these performances under standard 
conditions as well as under extremes with conditions of varied CVB in steady-state and 
varying slopes of tumour growth. In addition, we have tested the robustness of the 
algorithms by using extreme values for CVB and we have tested for variation in the 
exponential slopes of tumour growth. 
Parameters which interestingly could also be varied are sampling intervals or the starting 
points of the exponential tumour growth. 
In this study we have chosen a sampling interval of every two months, which is a relevant 
time schedule for monitoring of patients with breast cancer during follow-up after treatment 
(Söletormos et al., 2000b). Obviously, a sampling interval of one month could give earlier 
detection of tumour growth progression. However, in many of the algorithms the number of 
FP signals will simultaneously increase, and, conversely, longer sampling intervals will 
reduce FP signals, but true signals will be delayed. 
We have chosen arbitrarily the starting point of exponential tumour growth to be 1% of cut-
off. The impact on the performances of the algorithms when varying this starting point for 
the contribution from the growing tumour may be comparable for all the algorithms. If, for 
example, a starting point of 50% of the cut-off concentration was selected - the time for 
crossing cut-off would be shortened, so the progression detection time would possibly be 
earlier, whereas the percentages of FP would be unchanged for all algorithms. 
3.2 Future research 
In this investigation, we have investigated and challenged the seven algorithms, but the 
effect of sampling interval and of the start value of the contribution of marker from the 
tumour has not been studied. Furthermore, this computer model for simulations can be 
used for evaluation of other algorithms which can be tested and compared to the existing 
algorithms, before they are published or introduced in the clinic. 
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